Yoğun Bakım Hastasında Hepatit C Virüsünün Peg-İnterferon ve Ribavirin ile Tedavisi Atriyoventriküler Nodal Reenteran Taşikardiye Neden Olabilir

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"MS 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:1; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:variable; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Hepatit C virüsü (HCV) tedavisinde peginterferon (Peg-IFN)2b ve ribavirin tedavisi konvansiyonel interferon ve ribavirin tedavisinden daha etkilidir. Peg-IFN ve ribavirin tedavisinin önemli etkilerinin yanında ateş, halsizlik, heyecan, huzursuzluk, nötropeni ve trombositopeni gibi bir çok yan etki görülebilir. Ayrıca kardiyak aritmiler ve senkop gibi nadir olaylar da Peg-IFN tedavisine bağlı gelişebilir. Bizler bu çalışmada Peg-IFN ve ribavirin tedavisi sırasında presenkop atağı ve reenteran taşikardilerin en sık formu olan atriyoventriküler nodal reenteran taşikardi gelişen bir yoğun bakım hastasını sunuyoruz.

Treatment of Hepatitis C Virus with Peginterferon and Ribavirin May Trigger Atrioventricular Nodal Reentrant Tachycardia in An Intensive Care Unit Patient

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"MS 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:1; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:variable; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> The treatment of hepatitis C virus (HCV) with peginterferon (Peg-IFN) α2b and ribavirin is more effective than with conventional interferon and ribavirin. Despite the important effects of Peg-IFN and ribavirin therapy, many side effects, such as fever, fatigue, anxiety, irritability, neutropenia and thrombocytopenia, may be observed. In addition, cardiac arrhythmias and syncope are rare consequences of Peg-IFN therapy. In this study, we report an intensive care unit patient who developed atrioventricular nodal reentrant tachycardia (AVNRT), which is the most common type of reentrant supraventricular tachycardia, and presyncopal attack during Peg-IFN and ribavirin therapy.

___

  • 1. Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010;81:1351-7.
  • 2. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
  • 3. El-Atrebi K, El-Bassyouni HT. Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report. Cases J 2009;2:7429.
  • 4. Katritsis DG, Camm AJ. Atrioventricular nodal reentrant tachycardia. Circulation 2010;122:831-40.
  • 5. Yildiz M, Aykan AC, Kahveci G, Demir S, Ozkan M. Transvenous radiofrequency ablation theraphy as an effective and safe method for the treatment of the slow pathway of atrioventricular nodal re-entrant tachycardia. Koşuyolu Heart J 2011;14:51-5.
Koşuyolu Heart Journal-Cover
  • ISSN: 2149-2972
  • Yayın Aralığı: 3
  • Başlangıç: 1990
  • Yayıncı: Ali Cangül
Sayıdaki Diğer Makaleler

Haemostatic Effects of Topical Ankaferd Blood Stopper® On Bleeding Time in A Rat Abdominal Aortic Bleeding Model

Oruç Alper ONK, Hüseyin Serkan EROL, Fatih ÖZÇELİK, Ümit KAHRAMAN, Didem ONK, Erdim SERTOĞLU, Bilgehan ERKUT, Osman Nuri TUNCER, Ömer YİĞİNER, Mehmet AKSÜT

Atipik Seyirli Kladikasyo ve Popliteal Arter Anevrizmanın Eşlik Ettiği Popliteal Arter Tuzak Sendromu

Mustafa Bahadır İNAN, Fatih ADA, Mehmet TAŞAR, Evren ÖZÇINAR, Mehmet ÇAKICI, Sadık ERYILMAZ, Bülent KAYA, Adnan UYSALEL

Relationship Between Early Post-Pericardiotomy Syndrome and Atrial Fibrillation After Cardiac Surgery

Utkan SEVÜK, Fırat AYAZ, Aylin ERKUL, Kaan KÖSE, Ertan DEMİRDAŞ

Pankreas-Böbrek Nakili Hastalarda Koroner Arter Baypas Cerrahisi: Türkiye’deki İlk Olgu ve Literatürden Kısa Bir Derleme

Burçin ABUD, Cengiz ÖZBEK, Soysal TURHAN, Kemal KARAARSLAN, Yücel KARAMAN

Pulmoner Emboli Tarafından Saklanan Sır: Kolon Adenokarsinomu

Mithat SELVİ, Sevil ÖNAY, Tarkan TEKTEN

Popliteal Artery Entrapment Syndrome with Atypical Claudication and Popliteal Artery Aneurysm

Mehmet ÇAKICI, Evren ÖZÇINAR, Fatih ADA, Adnan UYSALEL, Bülent KAYA, Mustafa Bahadır İNAN, Mehmet TAŞAR, Sadık ERYILMAZ

Transfemoral Transkateter Aort Valv İmplantasyonu Sonrası Kontrast Bağımlı Nefropati Gelişiminde Femoral Giriş Yönteminin Önemi

İlker GÜL, Mustafa ZUNGUR, Ahmet TAŞTAN, Muhammed Esad ÇEKİN, Ahmet Çağrı AYKAN, Aysel İSLAMLI, Talat TAVLI

Sağ Ana Femoral Arterin Gerçek Anevrizması Sunumu

Muhammet Onur HANEDAN, Mehmet Ali YÜRÜK, Tanıl ÖZER, Uğur ZİYREK, İlker MATARACI

Importance of Femoral Access Method in Predicting the Development of Contrast Induced Nephropathy after Transfemoral Transcatheter Aortic Valve Implantation

İlker GÜL, Ahmet Çağrı AYKAN, Mustafa ZUNGUR, Ahmet TAŞTAN, Talat TAVLI, Aysel İSLAMLI, Muhammed Esad ÇEKİN

Association of Monocyte-to-HDL Cholesterol Ratio with Cardiac Syndrome X is Linked to Systemic Infl ammation

Selçuk PALA, Anıl AVCI, Elnur ALİZADE, Regayip ZEHİR, Mehmet Mustafa TABAKCI, Servet İZCİ, Ahmet GÜLER, Ahmet GÜNER